The popular weight loss drug Ozempic may potentially be linked to improving the cardiovascular health of millions of Britons around the UK.
The study, reported to potentially be one of the largest medical breakthroughs since Statin, a class of medications which reduce illness and mortality in individuals with heart diseases, provides insight into the success rates of Semaglutide.
The study was conducted by researchers at the University College London involving a total of 17,604 patients, 8803 receiving the drug.
Amongst the 8803 patients, those with pre-existing heart conditions and obesity found that the drug reduced the risk of a heart attack by 20%.
The researchers believe that these results are extremely beneficial in understanding and treating heart disease amongst patients with obesity.
Despite its controversial status, the drug Ozempic is now gaining recognition as a result of these findings.
Many believe that Ozempic is not a reliable and safe drug, concerning weight loss and its side effect, which may include gastrointestinal issues.
A similar study based on the same clinical trial revealed that patients reported an average weight loss of 10.2% when using the semaglutide drug found in Ozempic.
This study ultimately suggests that drugs like Ozempic and similar medications have the potential to transform the treatment of cardiovascular disease among patients with mild to severe obesity.
Despite the controversy surrounding Ozempic, these new waves of studies offer hope for individuals suffering with long-term cardiovascular issues.
